PDCD1 and melanoma: Preliminary data from the first 91 patients with anti-PD-1-failed disease (16 patients from the initial melanoma cohort plus 75 patients from the registration-directed cohort) demonstrated that RP1 plus nivolumab achieved an ORR of 37.4% (18.7% complete response rate), with responses observed in both injected and uninjected lesions.82